- Home
- VRAX vs PRFX Comparison
VRAX vs PRFX Comparison
Compare VRAX & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- PRFX
- Stock Information
- Founded
- VRAX 2013
- PRFX 2007
- Country
- VRAX United Kingdom
- PRFX Israel
- Employees
- VRAX N/A
- PRFX N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- PRFX Biotechnology: Pharmaceutical Preparations
- Sector
- VRAX Health Care
- PRFX Health Care
- Exchange
- VRAX Nasdaq
- PRFX Nasdaq
- Market Cap
- VRAX 2.8M
- PRFX 2.5M
- IPO Year
- VRAX 2022
- PRFX 2020
- Fundamental
- Price
- VRAX $0.52
- PRFX $1.10
- Analyst Decision
- VRAX Strong Buy
- PRFX
- Analyst Count
- VRAX 1
- PRFX 0
- Target Price
- VRAX $3.00
- PRFX N/A
- AVG Volume (30 Days)
- VRAX 278.3K
- PRFX 146.9K
- Earning Date
- VRAX 01-01-0001
- PRFX 11-14-2025
- Dividend Yield
- VRAX N/A
- PRFX N/A
- EPS Growth
- VRAX N/A
- PRFX N/A
- EPS
- VRAX N/A
- PRFX N/A
- Revenue
- VRAX $6,331.00
- PRFX N/A
- Revenue This Year
- VRAX $217,274.83
- PRFX N/A
- Revenue Next Year
- VRAX N/A
- PRFX N/A
- P/E Ratio
- VRAX N/A
- PRFX N/A
- Revenue Growth
- VRAX N/A
- PRFX N/A
- 52 Week Low
- VRAX $0.52
- PRFX $1.15
- 52 Week High
- VRAX $3.20
- PRFX $16.63
- Technical
- Relative Strength Index (RSI)
- VRAX 29.78
- PRFX 35.92
- Support Level
- VRAX $0.57
- PRFX $1.25
- Resistance Level
- VRAX $0.64
- PRFX $1.34
- Average True Range (ATR)
- VRAX 0.04
- PRFX 0.07
- MACD
- VRAX -0.01
- PRFX -0.01
- Stochastic Oscillator
- VRAX 0.06
- PRFX 0.00
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.